Drug intelligence / Profile preview

AN2533

Development stage: Preclinical
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

AN2533 is a small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, currently under development by Beijing Anlong Biomedical for the treatment of migraine. CGRP is a potent neuropeptide and vasodilator that plays a central role in the pathophysiology of migraine by mediating pain signaling and neurogenic inflammation within the trigeminovascular system. By blocking the CGRP receptor, AN2533 aims to inhibit these pathways to provide therapeutic relief for migraine patients. The program is currently in the IND-enabling stage of development.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on AN2533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN2533.

Explore the full profile